•  

    What’s New in Treatment for Castrate-Resistant Prostate Cancer?

    Emma Shtivelman, PhD

    About 10% to 20% of all prostate cancers are classified as castrate-resistant prostate cancer (CRPC). CRPC occurs when prostate cancer evolves to resist standard treatment with androgen deprivation therapy (ADT), which blocks the production and signaling activity of hormones called androgens (such as testosterone) that fuel the cancer’s growth. Most CRPCs are diagnosed as metastatic (mCRPC), meaning they have already spread beyond the prostate;… Read more »

  •   George Lundberg, MD

    Curated by Editor in Chief George Lundberg, MD, who notes:

    Medscape has published this excellent, authoritative, comprehensive overview of ovarian cancer, which includes information on diagnosis and treatment. (Written with a physician audience in mind.)

    .

  •   George Lundberg, MD

    Curated by Editor in Chief George Lundberg, MD, who notes:

    Rectal cancer is a subset of colon cancer but worth looking at somewhat differently because of its different location. If you wish to learn more, this presentation from Medscape is clear, detailed, unbiased, and worthy of full attention.

    .

  •   George Lundberg, MD

    Curated by Editor in Chief George Lundberg, MD, who notes:

    Small cell lung cancer is a common, particularly deadly form of lung cancer. If you wish to learn more, this authoritative encyclopedic discussion from Medscape should be very useful (written with a physician audience in mind).

    .

  •   George Lundberg, MD

    Curated by Editor in Chief George Lundberg, MD, who notes:

    Cancer that develops in the large intestine is known as colon cancer. This comprehensive, credible, and authoritative resourse from Medscape provides in-depth and up-to-date information on this disease.

    .

    .

  •   George Lundberg, MD

    Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

    The National Comprehensive Cancer Network (NCCN) recently made key updates to its clinical practice guidelines. This news story provides a summary of the updates.

    Go to full news story published by The ASCO Post.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Research paper from the Journal of Neurosurgery curated by Editor in Chief George Lundberg, MD, who notes: 

    The extent of tumor resection—how much of the tumor is able to be removed—at the initial surgery is probably the most important factor in prognosis of glioblastoma. This academic research paper explores methods that help surgeons maximize tumor removal.

    Go to full paper published in the Journal of Neurosurgery.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Research paper from Journal of Neuro-Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

    Tumor-treating fields (TTF) is a type of cancer treatment that uses alternating electric pulses. Its use for adults with high-grade gliomas remains controversial, and as outlined in this academic review paper, more high-quality research is needed.

    Go to full paper published in Journal of Neuro-Oncology.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Article from MedPage Today curated by Editor in Chief George Lundberg, MD, who notes: 

    Chemotherapy in the form of a single drug (as opposed to a combination of drugs) remains the best treatment for relapsed, platinum-resistant, serous, epithelial ovarian cancer. However, clinical trials are exploring new targeted therapy and immunotherapy options for this disease.

    Go to full article published by MedPage Today.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Article from GenomeWeb curated by Editor in Chief George Lundberg, MD, who notes: 

    The U.S. Food and Drug Administration (FDA) has approved the drug pembrolizumab (brand name Keytruda) for solid tumors based solely on whether they have a high tumor mutational burden—a high number of changes in the DNA of the cancer cells.

    Go to full article published by GenomeWeb.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.